Cooley LLP advised Outset, while Latham & Watkins LLP represented SLR Capital Partners in the transaction. Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering...
Outset Medical’s $300 Million Debt Facilities
Cordis’ Acquisition of MedAlliance
Latham & Watkins represented MedAlliance in the transaction. Swiss-based medical technology company MedAlliance announced it has entered into an agreement with Cordis for an acquisition which includes...
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Spectrum Pharmaceuticals’ $65 Million Debt Financing Agreement With SLR Capital Partners
Latham & Watkins represented Spectrum Pharmaceuticals in the deal. Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, has entered into...
Amgen’s $3 Billion Senior Unsecured Notes Offerings
Latham & Watkins represented Amgen in the offerings, while Shearman & Sterling represented represented the underwriters. Amgen Inc. executed a senior unsecured notes offerings consisting of US$1,250,000,000 4.050%...
Lindsay Goldberg’s Investment into MMS Holdings
Latham & Watkins represented Lindsay Goldberg in the transaction. MMS Holdings Inc. (MMS), a leading data-focused contract research organization (CRO), has announced that Lindsay Goldberg, a...
Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
Ascendis Pharma’s $400 Million ADSs Public Offering
Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction. Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of...